ANTI Stock Chart & Stats
$0.01
<$0.01(100.00%)
At close: 4:00 PM EDT
$0.01
<$0.01(100.00%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.01
Previous CloseN/A
Volume10.00K
Average Volume (3M)10.75K
Market Cap
$92.00
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-23.11
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding45,844,000
10 Day Avg. Volume10,750
30 Day Avg. Volume10,750
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ANTI FAQ
What was Antigenics Inc.’s price range in the past 12 months?
Antigenics Inc. lowest stock price was <$0.01 and its highest was $0.01 in the past 12 months.
What is Antigenics Inc.’s market cap?
Antigenics Inc.’s market cap is $92.00.
When is Antigenics Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Antigenics Inc.’s earnings last quarter?
Currently, no data Available
Is Antigenics Inc. overvalued?
According to Wall Street analysts Antigenics Inc.’s price is currently Overvalued.
Does Antigenics Inc. pay dividends?
Antigenics Inc. does not currently pay dividends.
What is Antigenics Inc.’s EPS estimate?
Antigenics Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Antigenics Inc. have?
Antigenics Inc. has 45,844,000 shares outstanding.
What happened to Antigenics Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Antigenics Inc.?
Currently, no hedge funds are holding shares in ANTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Antigenics Inc.
Antigenics, Inc., a clinical-stage biopharmaceutical company, discovers, manufactures, and develops immunotherapies for cancer. The company was founded in 1994 and is based in Lexington, Massachusetts.
Technical Analysis
Biodexa Pharmaceuticals
―
Scinai Immunotherapeutics
―
Aditxt
―
NewcelX
―
Virax Biolabs Group Ltd. Class A
―